Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
62.947,21
-1,24%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ ABVC BioPharma Inc (ABVC) ABVC BioPharma Inc (ABVC) Notizie

ABVC BioPharma Inc

ABVC
1,44
-0,15 (-9,43%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/4/202415:25GLOBEAiBtl BioPharma Inc. Acquired TT Life Company, Valued at..
17/4/202415:00GLOBEABVC BioPharma Executes a Global Licensing Definitive..
10/4/202414:30GLOBEABVC BioPharma Executes a Global Licensing Term Sheet for..
26/3/202413:30GLOBEABVC BioPharma Entered into a Global Licensing Deal of..
21/3/202413:30GLOBEAiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging..
19/3/202413:30GLOBEABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO..
14/3/202414:30GLOBEABVC BioPharma Reports Annual 2023 Financials and Provides..
29/2/202422:32EDGAR2Form 8-K/A - Current report: [Amend]
29/2/202422:31EDGAR2Form 8-K/A - Current report: [Amend]
27/2/202414:30GLOBEABVC's New Horizon for Oncology and Hematology Aims at..
16/2/202423:04EDGAR2Form S-1/A - General form for registration of securities..
15/2/202414:30GLOBEABVC BioPharma Executes a Definitive Agreement to Receive..
14/2/202401:59EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202414:30GLOBEABVC BioPharma Receives Australian Patent, Valid Until 2040,..
09/2/202423:04EDGAR2Form S-1/A - General form for registration of securities..
08/2/202415:30EDGAR2Form 8-K - Current report
08/2/202415:17GLOBEABVC Acquires $2.96 Million Worth of Land in Asia with..
17/1/202423:01EDGAR2Form 8-K/A - Current report: [Amend]
17/1/202423:00EDGAR2Form 8-K - Current report
17/1/202422:30EDGAR2Form 8-K - Current report
12/1/202423:01EDGAR2Form S-1 - General form for registration of securities under..
03/1/202413:24GLOBEABVC BioPharma and its Subsidiary Receive $460M From AiBtl..
07/12/202314:30GLOBEABVC BioPharma Announces Completion of Subject Treatment for..
05/12/202314:30GLOBEABVC BioPharma Shares Insights from Dr. Scott Irwin of..
21/11/202314:30GLOBEABVC BioPharma Receives U.S. Patent for ADHD Treatment, a..
20/11/202314:30EDGAR2Form 8-K - Current report
17/11/202323:00EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
17/11/202323:00EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
16/11/202316:05GLOBEABVC BioPharma Enters Definitive Agreement with Licensing..
16/11/202315:20EDGAR2Form 8-K - Current report
15/11/202315:00GLOBEABVC BioPharma Reports Third Quarter 2023 Financial and..
15/11/202314:41EDGAR2Form 8-K - Current report
15/11/202314:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
26/10/202314:30GLOBEABVC BioPharma Entered Into a Term Sheet to License Global..
17/10/202314:30GLOBEABVC BioPharma Announces Completion of Subject Recruitment..
09/10/202314:30GLOBEABVC BioPharma Receives Taiwanese Patent for Its Treatment..
13/9/202315:01EDGAR2Form 8-K - Current report
06/9/202314:30EDGAR2Form 8-K/A - Current report: [Amend]
31/8/202314:30EDGAR2Form 8-K - Current report
23/8/202314:30GLOBEABVC BioPharma Provides Updates on ADHD Phase IIb Clinical..
17/8/202323:00EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
17/8/202323:00EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
17/8/202315:19GLOBEABVC Executes Cooperation Agreement for Strategic..
17/8/202314:33EDGAR2Form 8-K - Current report
14/8/202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202314:30GLOBEABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid..
09/8/202323:00EDGAR2Form 8-K/A - Current report: [Amend]
07/8/202322:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
07/8/202314:30GLOBEABVC Corporate Update and CEO's Letter to Shareholders
07/8/202314:00EDGAR2Form 8-K - Current report
Apertura: 1,4901 Min: 1,40 Max: 1,57
Chiusura: 1,59

La tua Cronologia

NASDAQ
ABVC
ABVC BioPharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network